Aubrey Capital Management Ltd Purchases New Shares in Royalty Pharma plc (NASDAQ:RPRX)

Aubrey Capital Management Ltd purchased a new stake in Royalty Pharma plc (NASDAQ:RPRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,091 shares of the biopharmaceutical company’s stock, valued at approximately $926,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Allworth Financial LP raised its position in Royalty Pharma by 89.8% in the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 451 shares during the last quarter. Toroso Investments LLC increased its position in shares of Royalty Pharma by 0.9% during the 3rd quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock valued at $1,550,000 after purchasing an additional 504 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 531 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Royalty Pharma by 10.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 536 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in shares of Royalty Pharma by 8.0% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 607 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RPRX shares. The Goldman Sachs Group decreased their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Bank of America decreased their target price on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. JPMorgan Chase & Co. decreased their price objective on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Price Performance

Shares of RPRX traded down $0.11 during trading hours on Friday, reaching $28.00. 1,748,254 shares of the company’s stock traded hands, compared to its average volume of 2,545,847. The stock has a market cap of $16.73 billion, a PE ratio of 14.81 and a beta of 0.45. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61. The firm’s 50 day simple moving average is $29.61 and its 200-day simple moving average is $28.55. Royalty Pharma plc has a 12 month low of $25.92 and a 12 month high of $35.76.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. The firm had revenue of $736.00 million during the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. Equities analysts expect that Royalty Pharma plc will post 3.95 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.00%. Royalty Pharma’s dividend payout ratio is 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.